[Therapy of acute pancreatitis with a synthetic protease and phospholipase A2 inhibitor gabexate mesilate].

Abstract

In order to evaluate the efficacy and safety of gabexate mesilate (FOY = [ethyl-4-(6-guanidinohexanoyloxy) benzoate methane sulfonate]), a synthetic inhibitor of various proteases as well as phospholipase A 2, 17 patients with acute pancreatitis were treated with FOY in doses of 3 X 150 mg/day per i.v. perfusor. The clinical course of the disease and the laboratory findings were compared with the results of a control group of 21 patients also suffering from acute pancreatitis. 30% of the patients in the FOY-group and 40% in the control group had different complications during the first week after admission to the hospital. The laboratory findings in the two groups revealed that alpha-amylase levels in serum and urine in the FOY-group were significantly lower than in the control group. Side effects of the drug were not observed. FOY may be considered a promising drug for treatment of acute pancreatitis in view of its few side effects and especially with regard to its mode of action.

• Authors: J Freise
• Journal: Fortschritte der Medizin (Fortschr Med) Vol. 101 Issue 31-32 Pg. 1432-6 (Aug 25 1983) ISSN: 0015-8178 [Print] Germany
• Vernacular Title: Therapie der akuten Pankreatitis mit dem synthetischen Proteasen- und Phospholipase A2-Inhibitor Gabexat mesilat.
• PMID: 6194089 (Publication Type: Journal Article)

Chemical References

• Guanidines
• Protease Inhibitors
• Gabexate
• Phospholipases
• Phospholipases A
• Phospholipases A2
• Amylases

Topics

• Acute Disease
• Adult
• Aged
• Amylases (blood)
• Female
• Gabexate
• Guanidines (therapeutic use)
• Humans
• Male
• Middle Aged
• Pancreatitis (drug therapy, enzymology)
• Phospholipases (therapeutic use)
• Phospholipases A (therapeutic use)
• Phospholipases A2
• Protease Inhibitors (therapeutic use)